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Introduction {#sec1}
============

A critical issue for the immune system in mammals is to achieve a balance between protection and immune pathology. Much research has focused on the regulatory mechanisms of this balance and their dysfunction in a number of disease settings. In the specific setting of host infection and intracellular pathogens, it has been found that a wide range of pathogens directly hijack the immunoregulatory network during the course of infection. In the case of the Apicomplexa protozoan *Toxoplasma gondii*, the parasite has evolved methods to trigger a transient innate proinflammatory response that guarantees both control of the parasite population and survival of the host, promoting the establishment of a persistent cryptic parasite population (i.e., parasite survival) ([@bib32]). Like most pathogens, it has evolved numerous methods of hijacking cell-signaling pathways in order to survive in the host cell. As an obligate intracellular protozoan, it delivers effector proteins into its host cell ([@bib30], [@bib44]) to control mitogen-activated protein kinase (MAPK) signaling in macrophages, which in turn dictate parasite burden and disease ([@bib6], [@bib39]). MAPK signaling is characterized by a cascade of multiple kinases, through which the signal is transduced in the form of phosphorylation events from an upstream kinase to a downstream one ([@bib10], [@bib34]). The final phosphorylation event is a dual phosphorylation, which occurs on a conserved Thr-X-Tyr motif in the activation loop (AL) of the MAPK ([@bib12], [@bib14]). The phospho-residues are then able to bind basic patches, changing the relative orientation from open in the inactive state to closed in the active state allowing nucleotide binding in the active site ([@bib35], [@bib41]).

One of the effector proteins secreted by *T. gondii*, GRA24, has been shown to interact with the MAP kinase p38α, promoting its activation and nuclear translocation ([@bib6]). GRA24 encodes a 542 amino acid protein with an internal putative bipartite nuclear localization signal, and two repeats, R1 and R2, at the C terminus ([Figure 1](#fig1){ref-type="fig"}A). The mechanism by which GRA24 activates p38α, either directly or by modulating the existing activation pathway, is unknown. Previous experiments that mapped the region of the interactions between the two proteins in infected cells show that only one of the repeats is essential for the activation of p38α. Through a docking model, it was proposed that binding of p38α by GRA24 is driven by the kinase interaction motif (KIM), embedded in each of the two repeat regions ([Figure 1](#fig1){ref-type="fig"}A). KIMs are linear motifs used by kinases, phosphatases, substrates, and scaffold proteins to bind MAPKs at the KIM or D-motif binding site and regulate their activity ([@bib21], [@bib37], [@bib67]). KIMs ensure specificity between partners but also have allosteric effects on the proteins ([@bib15], [@bib58], [@bib66]).

Here, we have produced a recombinant complex of an N-terminal truncation of GRA24 (GRA24ΔN, [Figure 1](#fig1){ref-type="fig"}A) and p38α. Using a combinatorial approach of various structural techniques, the macrostructure of the recombinant complex between GRA24 and p38α and the crystal structure of the core interaction between the proteins is described. The results provide a molecular view of activation and define GRA24 as the only component required to activate p38α. The recombinant complex of GRA24 and p38α also provides a highly specific tool to determine the activity of p38α inhibitors that have advanced to clinical trials.

Results {#sec2}
=======

Structure of the GRA24KIM1-p38α Complex {#sec2.1}
---------------------------------------

To define the molecular basis of the interaction between p38α and GRA24, we determined the crystal structure of p38α bound to the GRA24 KIM1 peptide (residues 440--455) at 2.8 Å ([Table 1](#tbl1){ref-type="table"}). The complex crystallized in the triclinic space group *P*1 with two molecules in the asymmetric unit. The electron density for the GRA24KIM1-p38α complex was excellent and the entire peptide sequence could be traced ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As the density is slightly better in the second molecule (chain B), only this chain is used in subsequent descriptions. KIMs have a general consensus sequence of X-ϕ~U~-X~2~-(θ(Arg/Lys))~1-2~-(X)~2-6~-ϕ~L~-(X)~1-2~-ϕ~A~-X-ϕ~B~ (where ϕ~A~, ϕ~B~, ϕ~L~, and ϕ~U~ are hydrophobic residues \[usually Leu, Ile, or Val\] and θ is a basic residue \[Arg or Lys\]) ([@bib27], [@bib52]), shorter motifs can lack the first four residues ([@bib51], [@bib65]). The KIM or D-motif binding site is formed by an acidic patch known as the common docking (CD) domain ([@bib57]) and a hydrophobic docking groove ([@bib9], [@bib28]) ([Figure 1](#fig1){ref-type="fig"}B). The CD domain accommodates the ϕ~U~ and basic residues, while the hydrophobic docking groove binds ϕ~A~, ϕ~B~, and ϕ~L~ ([@bib2], [@bib31], [@bib42]). The GRA24 peptide binds with the hydrophobic residues (Φ~A~-Φ~B~) in the docking groove formed by α~d~ and α~e~ and the reverse turn between β~7~ and β~8~ in the C-terminal lobe of p38α ([Figure 1](#fig1){ref-type="fig"}B). Moreover, GRA24 utilizes all interacting motifs identified so far ([@bib48], [@bib65]), including the additional hydrophobic residues, Φ~L~ and Φ~U~, and the ionic contacts with the p38α CD domain, where the KIM1 peptide forms a short α helix involving residues RRELLG ([Figure 1](#fig1){ref-type="fig"}B). An additional hydrophobic interaction, not observed in other KIMs, is made with V447. Binding of GRA24KIM1 causes significant conformational change and disorder in the AL with a rotation of the N-terminal domain of 10° toward the C-terminal domain caused by tightening between the areas linked by the peptide ([Figure 1](#fig1){ref-type="fig"}C). This movement results in the alignment of the catalytic spine (C-spine) toward the active state, one of the essential events in kinase activation ([@bib43]), the residues belonging to the C-spine and the hinge region are in a similar position to the fully activated ATP bound p38γ ([@bib3]) ([Figure 1](#fig1){ref-type="fig"}C). The rearrangement also leads to a rotation of methionine 109 in the hinge region that prevents nucleotide binding in the active site of the inactive protein ([Figure 1](#fig1){ref-type="fig"}C). These conformational changes would allow the entry of ATP into the active site and make the AL accessible for phosphorylation between activated p38α molecules.

GRA24 Has High Affinity for p38α by Combining the Attributes of Different KIM Domains {#sec2.2}
-------------------------------------------------------------------------------------

To further characterize the interaction between GRA24 and p38α we compared the binding of GRA24 KIM1 with other KIM peptides described in the literature ([Table S1](#mmc1){ref-type="supplementary-material"}) using isothermal calorimetry (ITC). The GRA24 KIM1 peptide was found to bind p38α with an equilibrium dissociation constant (K~D~) of 1.6 μM ([Table S1](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}), ∼2-fold tighter than KIMs found in phosphatases, which have the highest measured affinity of cytosolic regulatory partners involved in classical MAPK regulation ([@bib23]). While the full-length proteins may show different affinities and binding modes, these results show that the GRA24 KIM has a higher affinity than either upstream kinases or downstream phosphatase KIMs.

The GRA24KIM1-p38α structure shows that high-affinity and allosteric effects (disorder of the AL) is achieved by combining the sequences of both the upstream MKK KIMs and those of the downstream phosphatases ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S3](#mmc1){ref-type="supplementary-material"}). To compare binding by an upstream kinase we determined a complex of a kinase dead mutant and the KIM domain from MKK6 (residues 4--18) at 2.4 Å (MKK6KIM-p38αK53R, [Table 1](#tbl1){ref-type="table"}) with no mutation in the KIM binding area, as there is in a published structure (C162S) ([@bib26]). The complex crystallized in the trigonal *P*3~1~21 space group with one molecule in the asymmetric unit. Comparison of the structures shows GRA24 binding in a similar manner to the hydrophobic groove, using the same L and I residues for Φ~A~-Φ~B~ but, unusually, uses the hydrophobic base of arginine in the Φ~L~ pocket ([Figure 2](#fig2){ref-type="fig"}C). This is a longer linker between Φ~L~ and Φ~B~ pockets than predicted and is more similar to the GRA24 KIM that has a double proline spacer. There is no interaction with the CD domain or the associated secondary structural rearrangement ([Figure S1](#mmc1){ref-type="supplementary-material"}B). None of the MAPKK-p38α structures available show binding to the CD domain. However, GRA24KIM1 binding to the p38α CD domain is similar to that described for tyrosine phosphatases ([Figure 2](#fig2){ref-type="fig"}B), the KIMs of which comprise an RR motif usually structured in a short α helix ([@bib66]).

The only KIM with a higher affinity for p38α is from the MAPK substrate MAPKAP kinase 2 (K~D~ of 50 nM; [@bib26]). As MAPKAPK2 is only present in the nucleus ([@bib64]) it will not compete with recruitment of p38α by GRA24 in the cytoplasm. Nevertheless, it is interesting to note that the GRA24 KIM1 has a very similar mode of binding to the MAPKAP2 KIM, both in the hydrophobic groove and to the CD domain, leading to very tight binding ([Figure 2](#fig2){ref-type="fig"}E). The major difference between the two KIMs is the reverse direction of the MAPKAP2 sequence ([Figure S3](#mmc1){ref-type="supplementary-material"}, C- to N-terminal) and increased secondary structure elements ([Figure 2](#fig2){ref-type="fig"}E).

The Structure of the GRA24ΔN-p38α Complex Shows Two Independent Kinases Bound to an Intrinsically Disordered Protein {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

To define the mechanism of activation of p38α by GRA24 the complex between the proteins must be studied; we therefore attempted to produce the protein in *Escherichia coli*. Expression of either the wild-type (WT) or a truncation removing the N terminus to the nuclear localization sequence (GRA24ΔN, residues 337--542, [Figure 1](#fig1){ref-type="fig"}A) failed to produce detectable expression. However, when co-expressed with p38α, a stable complex between p38α and GRA24ΔN was produced ([Figure S4](#mmc1){ref-type="supplementary-material"}) as the association with the kinase presumably prevents proteolysis. The complex was purified to homogeneity and analysis of staining intensity indicated a ratio of 1:2 for GRA24ΔN to p38α. We then investigated the structure of the complex using small-angle X-ray scattering (SAXS). SAXS was used to determine the average structure of the GRA24ΔN-p38α complex in solution ([Table S2](#mmc1){ref-type="supplementary-material"}). The radius of gyration was determined to be 4.85 nm with a D~max~ of 16.96 nm and ab initio modeling showing an elongated molecule ([Figures 3](#fig3){ref-type="fig"}A and 3B) best described by a disordered protein binding two globular domains. The pair distribution function ([Figure 3](#fig3){ref-type="fig"}A, inset) also suggests flexibility between the kinases (full width at half maximum of 3.8--6.2 nm about the mode of 4.85 nm) implying disorder in GRA24. The possibility that the dimer observed in the crystal structure could also be present in solution was tested by SAXS ([Table S2](#mmc1){ref-type="supplementary-material"}) and found to be a crystallization artifact.

Using the crystal structure of the GRA24KIM1-p38α complex and modeling GRA24 as an intrinsically disordered protein, a structure of the complex can be proposed ([Figures 3](#fig3){ref-type="fig"}B and 3C). The refined model is an excellent fit to the experimental curve (χ^2^ = 1.08) and provides insight into its mode of action ([Figures 3](#fig3){ref-type="fig"}A--3C). The two kinases are bound at the C terminus of GRA24, linked by ∼65 residues.

Dimerization has been demonstrated to be part of an activating mechanism for p38α and its close homolog ERK2 ([@bib17], [@bib38]). The presence of two KIMs in GRA24 opens the possibility that dimerization between the bound kinases could play a role in activation. The SAXS data imply movement between the kinases; however, as it only provides an average envelope of the structure the relationship between the kinases cannot be fully defined. We therefore used single-molecule approaches, negative-stain electron microscopy (EM), and atomic force microscopy (AFM), to investigate the dynamics of the complex. EM confirmed the flexibility, with class averages showing the two kinases in close proximity, but with a considerable variety of positions ([Figure 3](#fig3){ref-type="fig"}D). AFM also shows the dynamic nature of the complex at the single-molecule level ([Figure 3](#fig3){ref-type="fig"}E). In both AFM and EM data no secondary structure can be observed in GRA24 confirming its disordered nature. These data demonstrate flexibility between the kinases, eliminating the possibility of a dimer, which implies that the kinases can act independently.

We therefore tested the requirement in vivo of each of the KIMs specifically, by developing 293 derived inducible stable cell lines expressing hemagglutinin (HA) Flag-tagged GRA24 where either KIM1, KIM2, or both KIMs were mutated to alanine ([Figure 1](#fig1){ref-type="fig"}A). Immunoblotting for phosphorylated p38α demonstrates that GRA24 induces phosphorylation with only one KIM, but at least one is required for activity as the double mutant leads to an absence of activated p38α ([Figure 4](#fig4){ref-type="fig"}A). This is in agreement with previous results demonstrating that a single internal repeat domain was required for activation ([@bib6]). This result defines the GRA24-KIM as the essential factor in the recruitment and activation of p38α in vivo and that dimerization of the kinases is not required for activation.

The Recombinant Complex Is Active and Provides a Tool to Assess p38α Inhibitors {#sec2.4}
-------------------------------------------------------------------------------

The activity of the complex was assessed by assaying its ability to phosphorylate itself ([Figure 4](#fig4){ref-type="fig"}B) and also a typical transcription factor target of p38α, activating transcription factor 2 (ATF2) ([Figure 4](#fig4){ref-type="fig"}C). Incubation of the complex with radiolabeled ATP demonstrates the complex is active ([Figure 4](#fig4){ref-type="fig"}B) and mass spectrometry shows that phosphorylation occurs on multiple serine and threonine residues within GRA24 ([Table S3](#mmc1){ref-type="supplementary-material"}, [Figure 3](#fig3){ref-type="fig"}C), including a previously identified kinase motif ([@bib6]). Assaying the complex\'s activity against a natural target, ATF2, shows that p38α in complex with GRA24ΔN is significantly more active against ATF2 than p38α alone ([Figure 4](#fig4){ref-type="fig"}C). As both proteins were expressed in *E. coli*, devoid of endogenous protein kinases, this defines GRA24ΔN as the only factor required to activate p38α and demonstrates that the complex is a powerful tool to unambiguously evaluate the pharmacological inhibition of p38α in vitro. A highly active and stable recombinant form of p38α is not currently available, hampering efforts to assay the specific effects of molecules on p38α. Using the GRA24ΔN-p38α complex, we have shown that many of the inhibitors developed against p38α, some of which are currently in phase II clinical trials, prevent ATF2 phosphorylation by the complex in vitro ([Figure 4](#fig4){ref-type="fig"}C). The ability of the compounds to impair p38α phosphorylation, in a GRA24-dependent manner, and concomitant epidermal growth factor 1 (EGR1) activation was validated in infected macrophages ([Figure 4](#fig4){ref-type="fig"}D). Differences in the observed inhibition between in vivo and in vitro assays, as well as between different inhibitors ([Figures 4](#fig4){ref-type="fig"}C and 4D), demonstrate the importance of having a permanently active form of p38α.

Discussion {#sec3}
==========

Pathogens often evolve methods of modulating host cell-signaling pathways in order to promote their growth and persistence in the infected cell. One of the most efficient methods to interact with host signaling proteins is the use of intrinsically disordered proteins combined with short linear motifs, as the evolutionary timescales involved are shorter than those required for globular domains ([@bib13], [@bib24], [@bib29]). Short linear motifs in particular can be used to allow interactions between a pathogenic protein and that of a host in a simple manner ([@bib19]). This study demonstrates the molecular basis by which the parasite-derived agonist GRA24 bypasses the classical MAPK phosphorylation cascade and induces p38α auto-phosphorylation, forming an active complex able to activate transcription factors, such as ATF2.

The parasite protein operates through two atypical KIMs, embedded in an intrinsically disordered protein, which combine attributes of docking domains from multiple MAPK partners to maximize binding. A recent study has analyzed all known KIMs, identified many novel sequences, and classified them by their binding modes ([@bib65]). Differences are defined in the spacing between hydrophobic residues and the linker between the CD binding region and the docking groove region. Intriguingly, the GRA24 KIM borrows attributes from all the defined classes but does not fit in a single class ([Figures 2](#fig2){ref-type="fig"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}). Overall, it is closest to the HePTP class incorporating all hydrophobic residues as well as the short helix bound to the CD domain. Interestingly, its linker is the same length as the KIM from Ste7 ([Figure 2](#fig2){ref-type="fig"}F), and its binding mode for the hydrophobic groove exactly the same as that for Far1 ([Figure 2](#fig2){ref-type="fig"}D) with a larger spacer between the Φ~L~ and Φ~B~ pockets (double proline) ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}). Ste7 and Far1 are an activator and substrate, respectively, of yeast mating decision MAPKs, and the KIMs have no known higher eukaryotic equivalent. It is interesting to note that the binding mode of the GRA24 KIM is most similar to a unicellular eukaryote interaction pathway. KIMs perform many roles in the MAP kinase cascade, being present in upstream activating kinases, scaffold proteins, and deactivating phosphatases. Each partner uses the KIM to ensure specificity and control the protein allosterically. For example, the KIM from MKK6 loosely associates the two kinases and induces disorder in the AL making it available for phosphorylation. In contrast, phosphatase KIMs bind tightly and change the conformation of the AL to present the phospho-residues for dephosphorylation ([@bib66]). The first interaction must be transient to allow activated p38α to enter the nucleus and act on substrates, while the second must be long lived in order to tightly control the signal. On transport of the protein into the host cytoplasm the GRA24 KIMs will compete with the KIMs from regulatory pathways and induce conformational changes that allow ATP binding and the availability of the AL for *trans*-phosphorylation ([Figure 5](#fig5){ref-type="fig"}). The GRA24KIM-p38α structure shows that, in contrast to the so called third conformation of p38α ([@bib2]) or the conformation induced by TAB1 for *cis*-phosphorylation ([@bib15]), the kinase structure is very close to the active p38α and distinct from the inactive state. *trans*-Phosphorylation could occur both between the two kinase molecules bound to GRA24 and among kinases bound by different GRA24 molecules as in vivo data show that one R repeat is enough to promote p38α auto-phosphorylation ([Figure 4](#fig4){ref-type="fig"}). While two copies of the kinase are not necessary for activation, the possibility of phosphorylation between GRA24 kinase twins could enhance activity in a similar manner to scaffolding proteins ([@bib8]). GRA24 is itself then phosphorylated at multiple sites. Whether this has functional relevance or is just the result of an active kinase is not known, but a kinase recognition motif located between the bound kinases is highly phosphorylated, as are multiple serine and threonine residues throughout the protein ([Figure 3](#fig3){ref-type="fig"}C). Phosphorylation has been shown to play a role in protection of proteins from cellular proteases ([@bib16], [@bib18]) and also in nuclear translocation ([@bib45]), which could assist GRA24 in its role. At the N terminus, the rest of the protein is free, exposing the signal sequence to the nuclear transport machinery and allow the complex to be imported to the nucleus where it can act on specific transcription factors ([Figure 5](#fig5){ref-type="fig"}) ([@bib6]). The structural features described here show how high-affinity binding to p38α by GRA24 prevents deactivation by phosphatases and promotes a sustained host kinase activation during *Toxoplasma* infection. The tight control of the inflammatory signaling prevents either too weak a response leading to host death or too strong a response preventing invasion.

Following pathogen infection or tissue damage, p38α induces the expression of multiple genes that together regulate the inflammatory response. Therefore, interference in p38α kinase activity could aid in therapy for inflammatory disorders ranging from rheumatoid arthritis to chronic obstructive pulmonary disease. Compounds targeting p38α must be highly selective in order to avoid adverse side effects triggered by off-target kinase inhibition. Although in vitro p38 inhibition assays exist, they are hampered by the need to activate the MAPK either in vivo, e.g., following lipopolysaccharide treatment, or through in vitro MKK6 *trans*-phosphorylation ([@bib55]) and the short lived nature of the activated enzyme. By promoting a long-lasting activation of p38α, GRA24 challenges the natural-negative-feedback mechanisms that prevent the MAPK activation ad infinitum and offers a powerful in vitro tool to screen for small-molecule p38α inhibitors.

Experimental Procedures {#sec4}
=======================

Parasites and Host Cells {#sec4.1}
------------------------

Human foreskin fibroblast primary cells, and 293-TRex and J774 cell lines were cultured in DMEM (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen), 10 mM HEPES buffer (pH 7.2), 2 mM L-glutamine, and 50 μg/mL penicillin and streptomycin (Invitrogen). Cells were incubated at 37°C in 5% CO~2~. The *Toxoplasma* strains used in this study were RHku80 WT and RHku80 Δgra24 ([@bib6]).

Reagents {#sec4.2}
--------

Antibodies against HA (3F10; Roche), p38 MAPK (Cell Signaling Technology), Phospho-p38 MAPK (Cell Signaling Technology), Phospho-c-Fos (Ser32; Cell Signaling Technology), H4 Acetylated (EMD Millipore), EGR1 (Cell Signaling Technology), Phospho-ATF-2 (Thr71; Cell Signaling Technology), and HAUSP (Bethyl Laboratories) were used in the immunofluorescence assay and/or in western blotting. Immunofluorescence secondary antibodies were coupled with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen). Secondary antibodies used in western blotting were conjugated to alkaline phosphatase (Promega). The p38 inhibitors were purchased from InvivoGen and Euromedex.

Cloning, Expression, and Purification {#sec4.3}
-------------------------------------

DNA encoding human p38α was synthesized (ShineGene Bio-Technologies) and cloned into pETBS with an N-terminal His~6~-tag with a thrombin cleavage site. The mutant p38αK53R was obtained by PCR-based mutagenesis and verified by sequencing. Recombinant p38α and p38αK53R were expressed and purified following the same protocol. Both proteins were expressed in *E. coli* BL21 Rosetta2 cells (Novagen/Merck). Cells were lysed in lysis buffer (50 mM Tris \[pH 7.4\], 500 mM NaCl, 10 mM MgCl~2~, 1 mM DTT, 5% glycerol, and 10 mM imidazole) by mild sonication and the lysate was loaded onto a pre-packed His trap column (GE Healthcare). Protein was eluted with a linear gradient to 500 mM imidazole. Cleavage of the His~6~-tag was performed with thrombin overnight at 4°C in lysis buffer. After separation of cleaved and uncleaved protein, samples were further purified by size-exclusion chromatography using a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) in buffer A (50 mM Tris \[pH 7.4\], 50 mM NaCl, 10 mM MgCl~2~, 1 mM DTT, and 5% glycerol). Finally, the protein was loaded onto a Mono Q 5/50 GL (GE Healthcare) with a gradient to 1 M NaCl. This final step was necessary in order to separate the mono-phosphorylated protein from unphosphorylated protein. The protein was then concentrated to 10 mg/mL and stored at −20°C.

DNA encoding *T. gondii* GRA24 N-terminal truncation (GRA24ΔN) was synthesized (ShineGene Bio-Technologies) and cloned into pET28a using an N-terminal His~6~-tag with a thrombin cleavage site. BL21-CondonPlus(DE3)-RIL cells transformed with pETBS p38α were then additionally transformed with pET28a GRA24ΔN. Co-expression of p38α and GRA24ΔN was induced overnight at 18° with 0.2 mM isopropyl-thio-β-D-galactoside. Cells were lysed in lysis buffer (50 mM Tris \[pH 8.0\] and 250 mM NaCl) by mild sonication, and the lysate was loaded onto a pre-packed His trap column (GE Healthcare) in buffer A (50 mM Tris \[pH 8.0\], 250 mM NaCl, and 20 mM imidazole). The complex was eluted with a linear gradient to 300 mM imidazole. Pure fractions were pooled and dialyzed against buffer B (50 mM Tris \[pH 7.0\] and 50 mM NaCl) overnight and subsequently loaded onto a 5 mL HiTrap Q column (GE Healthcare) and eluted with a gradient to 1 M NaCl where the complex eluted as a single peak. The complex was then further purified by size-exclusion chromatography using a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) in buffer C (50 mM Tris \[pH 7.4\], 50 mM NaCl, and 5% glycerol).

The mutations in GRA24 were introduced in plasmids pcDNA-GRA24 WT-HA-Flag (HF) with the QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene). The following oligonucleotides for deletion of KIM sequence in the backbone vector pcDNA-GRA24 WT-HF vector ([@bib6]) were used: GRA24del506-515 (5′-AGA CTG GTC TTC TTG AGC GCA TCG TTA AAC CAC C-3′), GRA24del506-515-antisense 5′-GGT GGT TTA ACG ATG CGC TCA AGA AGA CCA GTC T-3′), GRA24del427-436 (5′-GAC TGG TCT TCT TGA GTA CAT CCC TCG TCC TC-3′), and GRA24del427-436-antisense (5′-GAG GAC GAG GGA TGT ACT CAA GAA GAC CAG TC-3′). The resulting plasmids were pcDNA-GRA24ΔKIM1, pcDNA-GRA24ΔKIM2, and pcDNA-GRA24ΔKIM1/ΔKIM2, respectively.

Isothermal Titration Calorimetry {#sec4.4}
--------------------------------

ITC was performed at 25°C using an iTC200 System (MicroCal, GE Healthcare). WT p38α or mutant proteins were dialyzed against the titration buffer (50 mM Tris \[pH 7.0\], 50 mM NaCl, and 1 mM DTT). MKK6 and GRA24 KIM peptides were also prepared in the same buffer. A 70 μM protein solution was titrated using 26 stepwise injections of 1.5 μL with each of the peptide solutions placed in the syringe. The GRA24 KIM peptide was used at 0.5 mM and the MKK6 peptide at 10 mM, the latter due to significantly lower affinity. The heat generated after each ligand injection was measured on the integral of the calorimetric signal. The resulting binding isotherms were analyzed by a nonlinear least-squares fit of the experimental data to a single site model ([@bib59], [@bib63]) using Microcal Origin 7.0 software. Experiments were duplicated and variability estimated to be 5% in the binding enthalpy and 10% for both the binding affinity and the number of sites.

In Vitro Kinase Assay {#sec4.5}
---------------------

Auto-phosporylation of the GRA24KIM-p38α complex was analyzed using a radioactivity-based assay. The complex (1.2 μg) was pretreated with λ-phosphatase (New England Biolabs) and incubated with 5 mM MgCl~2~ and 10 mM ATP (10:1 ATP-γP^32^) at room temperature. Reactions were run for 30 min and stopped by adding SDS-PAGE loading buffer. Samples were run on 12% SDS-PAGE and then exposed to film to visualize the extent of incorporation of P^32^.

ATF2 Assay {#sec4.6}
----------

Kinase reactions were performed in the presence of 100 μM ATP and 1 μg of ATF-2 fusion protein as a substrate. The phosphorylation of ATF-2 at Thr71 was measured by western blot using a Phospho-ATF-2 (Thr71) Antibody.

In Vivo Inhibition Assays {#sec4.7}
-------------------------

Specific pharmacological inhibition of GRA24-dependent p38α phosphorylation in J774 MØ was monitored following 18 hr of infection with RHku80 and RHku80 Δgra24 strains and by using specific p38 inhibitors, control inhibitors, and DMSO vehicle.

293-TRex Transfection {#sec4.8}
---------------------

Twenty-four hours before transfection, cells were plated (80% confluency) in six-well tissue culture dishes. Flag-fusion protein-expressing plasmids (1 μg) and 0.1 μg puromycin selection plasmid were co-transfected into 293-TRex cells with Lipofectamine reagent (Invitrogen) according to the manufacturer\'s instructions. Seventy-two hours later, cells were diluted in the presence of 5 μg/mL puromycin (Sigma-Aldrich) for selection. Individual drug-resistant clones were expanded and tested for tetracycline-inducible gene expression.

Crystallization {#sec4.9}
---------------

Crystallization conditions were established at the EMBL High Throughput Crystallization Laboratory (Grenoble, France). To obtain crystals of p38α in complex with the KIM peptide from GRA24 (GRA24KIM1-p38α) protein was incubated overnight at 4°C with a 3-fold molar excess of peptide GLLERRGVSELPPLYI (Eurogentec). The complex was then mixed 1:1 with 0.2 M MgCl~2~, 0.1 M Tris/HCl (pH 8.5), and 25%--28% PEG 3350 and set up in sitting-drop plates. Crystals were harvested directly from the mother liquor ([@bib46]) using a MicroMesh loop (MiTeGen), plunged into liquid nitrogen, and stored at 70 K.

For p38αK53R in complex with the MKK6 peptide (MKK6KIM-p38αK53R), protein was incubated overnight at 4°C with a 3-fold molar excess of peptide SKGKKRNPGLKIPKA (Eurogentec). Crystals were obtained as above but equilibrated against a buffer containing 25% (w/v) PEG 3350 and 0.1 mM Bis-Tris (pH 6.5). Crystals were transferred to a cryoprotection buffer, prepared as described above (reservoir supplemented with 20% \[v/v\] PEG 400) and harvested using a MicroMesh loop, plunged into liquid nitrogen, and stored at 70 K.

Data Collection and Structure Solution {#sec4.10}
--------------------------------------

Diffraction data were collected at beamline ID23-2 ([@bib22]) at the ESRF (Grenoble, France) on a MAR225 charge-coupled device detector to between 2.4 and 2.8 Å resolution. Crystals of MKK6KIM-p38αK53R formed long needles (with approximate dimensions of 100 × 20 × 20 μm^3^) that were difficult to visualize. Crystals of the GRA24KIM-p38α complex were 500 μm in the largest dimension and displayed considerable heterogeneity in diffraction quality ([@bib4]). Crystals were centered using automated mesh scans ([@bib5], [@bib7], [@bib25], [@bib53]). The MKK6KIM-p38αK53R complex crystallized in the trigonal space group *P*3~1~2~1~, with one molecule in the asymmetric unit and the GRA24KIM-p38α complex crystallized in the triclinic space group *P*1 with two molecules in the asymmetric unit ([Table 1](#tbl1){ref-type="table"}). Data were processed with XDS ([@bib36]) and programs from the Collaborative Computational Project Number 4 suite ([@bib62]). The structures were solved by molecular replacement using MolRep ([@bib60]). For the p38αK53R structure (PDB: [1WFC](pdb:1WFC){#intref0010}; [@bib33]) was used as a search model with all water molecules removed. For the p38α and MKK6KIM-p38αK53R structures, the p38αK53R structure was used as a search model. Refinement was carried out alternately using Phenix ([@bib1]) and by manual rebuilding with COOT ([@bib20]). For the GRA24KIM-p38α complex, tight NCS restraints between monomers in the asymmetric unit were used at the beginning of refinement. Models were validated using MolProbity ([@bib11]).

SAXS Experiments {#sec4.11}
----------------

SAXS data were collected at the bioSAXS beamline BM29 ([@bib47]) at the ESRF with a PILATUS 1 M detector (Dectris) at a wavelength of 0.992 Å and a camera length of 2.87 m. Scattering curves were measured from solutions of p38α without substrates, in complex with the GRA24 peptide, and of the GRA24KIM-p38α complex. Measurements were performed at protein concentrations between 2 and 15 mg/mL to verify that any inter-particle effects that may have been present could be accounted for and rule out their influence on the analysis. To exclude the possibility of radiation damage, ten frames, each of 1 s duration, were collected while continuously exposing fresh samples to the beam, the resulting frames were then compared to ensure that no differences in the SAXS profiles were induced by exposure to X-rays. All data were processed using the ATSAS program package ([@bib49]). Radii of gyration (R~g~) were evaluated from Guinier plots using PRIMUS ([@bib40]) and pair distance distribution functions, *P(r)*, were computed with GNOM ([@bib54]). The model of the GRA24KIM-p38α complex was refined using CORAL ([@bib50]).

Electron Microscopy {#sec4.12}
-------------------

The GRA24KIM-p38α complex was absorbed to the clean side of a carbon film on mica, stained with 2% sodium silicotungstate, and transferred to a 400-mesh copper grid. The images were taken under low-dose conditions (\<10 e^−^/Å^2^) at a nominal magnification of 49,000× with defocus values between 1.2 and 2.5 μm on an FEI Tecnai 12 electron microscope at 120 kV accelerating voltage using Kodak S0-163 films. Four micrographs were scanned with a Zeiss scanner at 7 μm pixel size (3.2 Å on the sample scale). Using EMAN2 ([@bib56]), 237 views of the complex were selected, interactively boxed into 200 × 200 pixel boxes. Class averages were produced using IMAGIC ([@bib61]).

Atomic Force Microscopy {#sec4.13}
-----------------------

Samples were adsorbed to mica plates at a concentration of 0.1 mg/mL. A Chypher AFM (Asylum Research, Oxford Instruments) was used with MSNL cantilevers (Bruker) in AFM amplitude modulation mode.
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![Structure of the GRA24KIM1-p38α Complex\
(A) Diagram of GRA24, KIM deletion mutants, and N-terminally truncated constructs used in this study. Signal peptide (red), nuclear localization signal (blue), internal repeats (purple), and KIM (yellow) sequences are shown.\
(B) The structure of p38α is shown as a solvent accessible surface colored by electrostatic potential (−10 to 10 kTe^−1^, red to blue) and the GRA24KIM1 peptide is shown in cartoon representation with side chains as sticks (yellow). Details of the interactions between p38α and GRA24KIM1 are inset. GRA24 uses all the classical interactions (ɸ~A~, ɸ~B~, ɸ~L~, ɸ~U~, and RR) as well as an additional hydrophobic interaction with V447.\
(C) Conformational changes induced by GRA24KIM1 binding allow nucleotide entry to the active site (inactive conformation PDB: [5ETC](pdb:5ETC){#intref0045}, active conformation PDB: [1CM8](pdb:1CM8){#intref0050}). The rearrangement of the C-spine (Val38, Ala51, Ala157, Leu156, Val158, Leu113, Ile212, and Leu216) from the inactive to active state is highlighted by the movement of Val38.](gr1){#fig1}

![Comparison of the Binding Modes of KIMs\
(A) The GRA24 KIM. Residues that interact directly are shown as sticks.\
(B) Comparison with the phosphatase PTP KIM, GRA24, and the PTP KIM have a very similar binding to the CD domain with the ɸ~U~ and RR residues but diverge as the hydrophobic groove is approached.\
(C) Comparison with the p38-activating kinase MKK6 KIM: similar binding is observed in the hydrophobic groove with a larger space between the ɸ~B~ and ɸ~L~ pockets.\
(D) Comparison with the yeast MAPK substrate Far1 KIM, a very similar mode of binding is observed that only diverges at the CD domain.\
(E) Comparison with the p38 substrate MAPKAP2 KIM that has the highest affinity and runs C- to N-terminal left to right. The interactions are very similar despite the additional secondary structure and reverse binding.\
(F) Comparison with the yeast Ste7 KIM. The two KIMs are very similar in sequence but binding diverges slightly at the CD domain. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Structure of the GRA24ΔN-p38α Complex\
(A) Scattering curve of the GRA24ΔN-p38α complex: the fit of models (B) and (C) is shown in blue and the pair distribution function is shown in the inset.\
(B) Ab initio model of the GRA24ΔN-p38α complex (blue mesh) with the final model (internal repeats, purple; KIM, yellow; p38α is shown with N-terminal lobes in gray, C-terminal in green, and AL in blue).\
(C) Model of the GRA24ΔN-p38α complex, colored as in (B), in stereo showing phosphorylation sites (magenta) identified by mass spectrometry ([Table S3](#mmc1){ref-type="supplementary-material"}) scaled according to the number of times found.\
(D) Class averages from negative-stain EM of the GRA24ΔN-p38α complex. Arrows indicate class averages where the two p38α molecules are separated; considerable variety in the orientation of the two kinases is observed. The SAXS model is shown to scale for reference.\
(E) The GRA24ΔN-p38α complex visualized by AFM, kinase pairs are observed in multiple conformations.](gr3){#fig3}

![Activity of the GRA24ΔN-p38α Complex\
(A) p38α phosphorylation in 293-TRex cells stably expressing GRA24 WT or KIM mutants. Nuclear fractions were immunoblotted with the indicated antibodies. Data are representative of three experiments.\
(B) Auto-phosporylation of the GRA24ΔN-p38α complex was analyzed using a radioactivity-based assay, the third lane (Mg^∗^) was treated with λ-phosphatase before the assay.\
(C) Analysis of p38α MAP kinase activity by western blot using Phospho-ATF-2 (Thr71) Antibody and its inhibition by known kinase inhibitors. A selection of p38α inhibitors is shown to have a variety of effects on the inhibition of target phosphorylation. Inhibitors of upstream MKKs and JNK (PD98059 and SP600125) are shown as controls.\
(D) Specific pharmacological inhibition of GRA24-dependent p38α phosphorylation in J774 MØ. Cells infected with WT or *Δgra24* KO parasites were incubated for 18 hr with p38 inhibitors (15 μM), control SAPK/JNK (SP600125, 25 μM), and MKK (PD98059, 15 μM) inhibitors as well as DMSO vehicle. Nuclear fractions were immunoblotted with the indicated antibodies.](gr4){#fig4}

![Model of How GRA24 Subverts MAP Kinase Signaling\
GRA24 is secreted from the parasitophorous vacuole into the host cell cytoplasm where its high-affinity KIM sequence will recruit p38α. On binding GRA24, p38α is sequestered from regulatory kinases and phosphatases and can bind ATP allowing phosphorylation of the activation loop between and within complexes. The p38α-GRA24 complex is now a highly efficient active complex that can be translocated to the nucleus allowing a sustained and regular inflammatory response.](gr5){#fig5}

###### 

Data Processing and Refinement Statistics for the GRA24KIM1-p38α and MKK6KIM-p38αK53R Structures

  Structure                    GRA24KIM-p38α (5ETA)   MKK6KIM-p38αK53R (5ETF)
  ---------------------------- ---------------------- -------------------------
  **Data Collection**                                 
                                                      
  Space group                  *P*1                   *P*3~1~21
  Unit cell dimensions                                
  a, b, c (Å)                  52.0, 61.9, 75.7       82.4, 82.4, 123.3
  α, β, γ (°)                  105.6, 96.3, 114.7     90.0, 90.0, 120.0
  Resolution range (Å)         45.79 (2.95--2.8)      46.65 (2.49--2.4)
  R~meas~                      0.09 (0.27)            0.108 (0.690)
  \<I/σ(I)\>                   9.9 (3.0)              13.3 (2.1)
  Redundancy                   1.9 (1.9)              3.9 (3.9)
  Completeness (%)             96.5 (97.2)            90.3 (59.0)
                                                      
  **Refinement**                                      
                                                      
  Resolution range (Å)         20.0 (2.95--2.8)       20.0 (2.49--2.4)
  No. of reflections           36,372                 32,069
  R~work~/R~free~              22.3/28.3              16.29/23.1
  No. of atoms                                        
  Protein                      2,715 (A), 2,705 (B)   2,725
  127 (C), 127 (D) GRA24KIM1   92 (MKK6KIM)           
  Water                        29                     223
  B factors (Å^2^)                                    
  Protein                      63.69 (A), 59.98 (B)   32.25
  Ligand                       73.97 (C), 83.91 (D)   42.33
  Water                        46.87                  33.48
  RMSD                                                
  Bond lengths (Å)             0.006                  0.0078
  Bond angles (°)              1.113                  0.931
  Ramachandran favored (%)     95.8                   97.7
  Ramachandran outliers (%)    0.4                    0
  Rotamer outliers (%)         2.2                    1.3
  Clash score                  9.68                   4.82
  Overall score                2.07                   1.41

Values in parentheses are for the outer resolution shell.

RMSD, root-mean-square deviation.

[^1]: Lead Contact
